Cutler Capital Management’s AbbVie ABBV Stock Holding History

Cutler Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$410K	Sell	1,629 -286	-15%	-$61.5K	0.11%	89
2026 Q1	$416K	Hold	1,915	–	–	0.11%	89
2025 Q4	$438K	Hold	1,915	–	–	0.13%	94
2025 Q3	$443K	Buy	1,915 +8	+0.4%	+$1.63K	0.14%	90
2025 Q2	$354K	Sell	1,907 -212	-10%	-$39.4K	0.12%	89
2025 Q1	$444K	Sell	2,119 -281	-12%	-$54.6K	0.15%	85
2024 Q4	$426K	Sell	2,400 -386	-14%	-$71K	0.15%	89
2024 Q3	$550K	Sell	2,786 -1,000	-26%	-$187K	0.19%	86
2024 Q2	$649K	Sell	3,786 -63	-2%	-$10.4K	0.25%	78
2024 Q1	$701K	Buy	3,849 +34	+0.9%	+$5.86K	0.28%	73
2023 Q4	$591K	Buy	3,815 +139	+4%	+$20.3K	0.24%	73
2023 Q3	$548K	Buy	3,676 +35	+1%	+$5.14K	0.25%	72
2023 Q2	$490K	Sell	3,641 -359	-9%	-$52.6K	0.23%	73
2023 Q1	$637K	Sell	4,000 -66,000	-94%	-$10.1M	0.28%	70
2022 Q4	$1.13M	Buy	+70,000	New	+$10.7M	0.47%	59
2016 Q3	–	Sell	-3,100	Closed	-$192K	–	82
2016 Q2	$192K	Sell	3,100 -2,000	-39%	-$122K	0.05%	80
2016 Q1	$291K	Buy	5,100 +500	+11%	+$27.9K	0.14%	71
2015 Q4	$272K	Buy	4,600 +1,500	+48%	+$86.4K	0.13%	73
2015 Q3	$169K	Hold	3,100	–	–	0.08%	80
2015 Q2	$208K	Buy	+3,100	New	+$202K	0.09%	72

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cutler Capital Management's ABBV Position: Q2 2026 in Review

Cutler Capital Management reduced its AbbVie (ABBV) stake by 15% in Q2 2026, selling an estimated $61.5K and leaving 1,629 shares worth $410K. The position accounts for 0.11% of the portfolio, ranked #89.

Cutler Capital Management first reported a position in ABBV in Q2 2015 and has held it in 20 quarters since. The position peaked at $1.13M in Q4 2022. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Cutler Capital Management held 1,629 shares of AbbVie worth $410K as of Q2 2026.
Cutler Capital Management sold 286 AbbVie shares in Q2 2026, an estimated $61.5K.
AbbVie made up 0.11% of Cutler Capital Management's portfolio in Q2 2026, its #89 holding.
Cutler Capital Management first reported a position in AbbVie in Q2 2015 and has held it in 20 quarters since.
Cutler Capital Management's AbbVie position peaked at $1.13M in Q4 2022.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cutler Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.